A Dose Escalating Study of Oxaliplatin and High Dose Weekly Leucovorin and 5-Fluorouracil in Patients with Advanced Solid Tumors

References

• Raymond, E.; Chaney, S G.; Taamma, A.; Cvitkovic, E. Oxaliplatin: a review of preclinical and clinical studies.Ann. Oncol. 1998, 9, 1053–1071. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Reed, E.; Paull, K.; Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.Biochem. Pharmacol. 1996, 52, 1855–1865. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Woynarowski, J M.; Napier, C.; Koester, S K.; Chen, S F.; Troyer, D.; Chapman, W.; MacDonald, J R. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).Biochem. Pharmacol. 1997, 54, 1181–1193. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bleiberg, H. Oxaliplatin (L-OHP): a new reality in colorectal cancer.Br. J. Cancer 1998, 77 (Suppl. 4), 1–3. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.Anti-Cancer Drugs 1997, 8, 876–885. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• de Gramont, A.; Vignoud, J.; Tournigand, C.; Louvet, C.; Andre, T.; , et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.Eur. J. Cancer 1997, 33, 214–219. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; , et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J. Clin. Oncol. 2000, 18, 2938–2947. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Levi, F A.; Zidani, R.; Vannetzel, J M.; Perpoint, B.; Focan, C.; , et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.J. Natl. Cancer Inst. 1994, 86, 1608–1617. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Levi, F.; Zidani, R.; Misset, J L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.Lancet 1997, 350, 681–686. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Giacchetti, S.; Perpoint, B.; Zidani, R.; Le Bail, N.; Faggiuolo, R.; , et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.J. Clin. Oncol. 2000, 18, 136–147. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bertheault-Cvitkovic, F.; Jami, A.; Ithzaki, M.; Brummer, P D.; Brienza, S.; , et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.J. Clin. Oncol. 1996, 14, 2950–2958. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kouroussis, Ch.; Agelaki, S.; Mavroudis, D.; Kakolyris, S.; Androulakis, N.; , et al. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.Anticancer Res. 2003, 23, 785–792. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mavroudis, D.; Pappas, P.; Kouroussis, Ch.; Kakolyris, S.; Agelaki, S.; , et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.Ann. Oncol. 2003, 14, 304–312. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cvitkovic, E.; Misset, J L. Chemotherapy for ovarian cancer.N. Engl. J. Med. 1996, 334, 1269 author reply 1270. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Louvet, C.; Andre, T.; Tigaud, J M.; Gamelin, E.; Douillard, J Y.; , et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.J. Clin. Oncol. 2002, 20, 4543–4548. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Louvet, C.; Andre, T.; Lledo, G.; Hammel, P.; Bleiberg, H.; , et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.J. Clin. Oncol. 2002, 20, 1512–1518. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Extra, J M.; Marty, M.; Brienza, S.; Misset, J L. Pharmacokinetics and safety profile of oxaliplatin.Semin. Oncol. 1998, 25, 13–22. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• de Gramont, A.; Bosset, J F.; Milan, C.; Rougier, P.; Bouche, O.; , et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.J. Clin. Oncol. 1997, 15, 808–815. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vanhoefer, U.; Harstrick, A.; Kohne, C H.; Achterrath, W.; Rustum, Y M.; , et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.J. Clin. Oncol. 1999, 17, 907–913. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Grothey, A.; Deschler, B.; Kroening, H.; Ridwelski, K.; Reichardt, P.; , et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC).Proc. Am. Soc. Clin. Oncol. 2002, 20, 512 (abstr.). [CSA]
   Google Scholar
• A Guideline for the Use of Neurontin in the Management of Neuropathic Pain. Washington Department of Labor and Industries, Washington State Medical Association. Guideline for the Use of Neurontin in the Management of Neuropathic Pain; Washington Department of Labor and Industries, Washington State Medical Association: Seattle, WA, 2002, 5 p.
   Google Scholar
• Di Palma, M.; Poulain, P.; Pichard, E. What's new in the treatment of cancer pain?. Bull. Cancer 2004, 91, 95–98. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar